HLA-A*03:01 (Tetramer) protein (KRAS G12V)
宿主: 人
宿主: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
-
- 抗原
- HLA-A*03:01
- 蛋白类型
- Recombinant
- 产品特性
- Tetramer
- 宿主
- 人
-
资源
- HEK-293 Cells
- 标记
- KRAS G12V
- 原理
- Human HLA-A*03:01 & B2M & KRAS G12V (VVVGAVGVGK) Tetramer Protein
- 序列
- Gly25-Thr305 (HLA-A*03:01), Ile21-Met119 (B2M) and VVVGAVGVGK peptide
- 特异性
- Uni-Prot: NP_002107.3 (HLA-A*03:01), P61769 (B2M), VVVGAVGVGK
- 产品特性
- Recombinant Human HLA-A*03:01 & B2M & KRAS G12V (VVVGAVGVGK) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin.It contains Gly25-Thr305(HLA-A*03:01),Ile21-Met119(B2M) and VVVGAVGVGK peptide.
- 纯度
- > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
- 过滤
- 0.22 μm filtered
- 内毒素水平
- Less than 1EU per μg by the LAL method.
- Biological Activity Comment
- Immobilized Human KRAS G12V (HLA-A*03:01) Tetramer, His Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-KRAS G12V (HLA-A*03:01) Antibody, hFc Tag with the EC50 of 0.58μg/ml determined by ELISA (QC Test). The affinity constant of 42.3 nM as determined in SPR assay (Biacore T200). See testing image for detail.
-
-
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 溶解方式
- Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.
- 缓冲液
- Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.
- 储存条件
- -20 °C,-80 °C
- 储存方法
- -20 to -80°C for 12 months as supplied from date of receipt., -80°C for 3-6 months after reconstitution., 2-8°C for 2-7 days after reconstitution., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- 有效期
- 12 months
-
- 抗原
- HLA-A*03:01
- 背景
- Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
- 分子量
- 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.
- NCBI登录号
- NP_002107
-
You are here:
